These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 14498755)

  • 1. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders.
    Tabrizchi R
    Drugs; 2003; 63(20):2185-202. PubMed ID: 14498755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
    Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopeptidase inhibitors.
    Weber MA
    Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopeptidase inhibition: a novel approach to cardiovascular therapy.
    Floras JS
    Can J Cardiol; 2002 Feb; 18(2):177-82. PubMed ID: 11875587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
    Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
    Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O; Reeves RA
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopeptidase inhibition: effective blood pressure control for vascular protection.
    Quaschning T; Ruschitzka F; Lüscher TF
    Curr Hypertens Rep; 2002 Feb; 4(1):78-84. PubMed ID: 11790296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined neutral endopeptidase inhibitors.
    Cuculi F; Erne P
    Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Omapatrilat--new drug for patients with hypertension and heart failure].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
    Lüscher TF; Wenzel RR; Moreau P; Takase H
    Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ACE inhibitors in the treatment of hypertension in elderly patients].
    Evéquoz D; Reichenstein T; Waeber B; Nussberger J; Brunner HR
    Schweiz Rundsch Med Prax; 1991 Jun; 80(25):701-6. PubMed ID: 1857901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.